Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.

Chad A. Brown, Jack L Lesher, Christopher M. Peterson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Xanthomas most often occur in conjunction with a primary or secondary disorder of lipid metabolism. A range of metabolic disturbances has been described in association with protease inhibitors, including lipodystrophy, hyperglycemia, and hyperlipidemia. Ritonavir has been repeatedly shown to be the most common protease inhibitor to induce these metabolic abnormalities. This report highlights a case of both tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
Volume52
Issue number5 Suppl 1
StatePublished - Jan 1 2005

Fingerprint

Xanthomatosis
Ritonavir
Hyperlipidemias
Protease Inhibitors
Lipid Metabolism Disorders
Lipodystrophy
Hyperglycemia

ASJC Scopus subject areas

  • Dermatology

Cite this

Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia. / Brown, Chad A.; Lesher, Jack L; Peterson, Christopher M.

In: Journal of the American Academy of Dermatology, Vol. 52, No. 5 Suppl 1, 01.01.2005.

Research output: Contribution to journalArticle

Brown, Chad A. ; Lesher, Jack L ; Peterson, Christopher M. / Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia. In: Journal of the American Academy of Dermatology. 2005 ; Vol. 52, No. 5 Suppl 1.
@article{7f7cd593a07e420da3b1a27940d1eb26,
title = "Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.",
abstract = "Xanthomas most often occur in conjunction with a primary or secondary disorder of lipid metabolism. A range of metabolic disturbances has been described in association with protease inhibitors, including lipodystrophy, hyperglycemia, and hyperlipidemia. Ritonavir has been repeatedly shown to be the most common protease inhibitor to induce these metabolic abnormalities. This report highlights a case of both tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.",
author = "Brown, {Chad A.} and Lesher, {Jack L} and Peterson, {Christopher M.}",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
volume = "52",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5 Suppl 1",

}

TY - JOUR

T1 - Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.

AU - Brown, Chad A.

AU - Lesher, Jack L

AU - Peterson, Christopher M.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Xanthomas most often occur in conjunction with a primary or secondary disorder of lipid metabolism. A range of metabolic disturbances has been described in association with protease inhibitors, including lipodystrophy, hyperglycemia, and hyperlipidemia. Ritonavir has been repeatedly shown to be the most common protease inhibitor to induce these metabolic abnormalities. This report highlights a case of both tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.

AB - Xanthomas most often occur in conjunction with a primary or secondary disorder of lipid metabolism. A range of metabolic disturbances has been described in association with protease inhibitors, including lipodystrophy, hyperglycemia, and hyperlipidemia. Ritonavir has been repeatedly shown to be the most common protease inhibitor to induce these metabolic abnormalities. This report highlights a case of both tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.

UR - http://www.scopus.com/inward/record.url?scp=33644876125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644876125&partnerID=8YFLogxK

M3 - Article

C2 - 15858517

AN - SCOPUS:33644876125

VL - 52

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 5 Suppl 1

ER -